Skip to main content

Table 4 Study 2. Comparison between two groups of infants (≤2y/o) diagnosed of RSV infection

From: SOFIA®RSV: prospective laboratory evaluation and implementation of a rapid diagnostic test in a pediatric emergency ward

 

Group 2

Delayed RSV diagnosis at the laboratory (n = 47)

Group 3

RSV diagnosis at POCT (n = 160)

P-value

% of infants with RSV diagnosis

Clinical Symptoms

 Gestational age under 37 weeks

26% (n = 12)

14% (n = 22)

NS

16.43

 Age under 6 months

72% (n = 34)

85% (n = 136)

<0.05

82.13

 Temperature above 38 °C

36% (n = 17)

42% (n = 67)

NS

40.60

 Signs of Respiratory Distress

68% (n = 32)

89% (n = 143)

<0.001

84.54

 Feeding Difficulties

32% (n = 15)

33% (n = 52)

NS

32.37

Final diagnosis

 Bronchiolitis

64% (n = 30)

91% (n = 145)

<0.001

84.54

 Pneumopathy

6% (n = 3)

9% (n = 15)

NS

8.71

 Asthma

9% (n = 4)

3% (n = 5)

NS

4.35

Patients Management

 Corticosteroids

60% (n = 28)

72% (n = 115)

NS

69.08

 Antibiotics

23% (n = 11)

20% (n = 32)

NS

20.77

 Aerosol Therapy

72% (n = 34)

86% (n = 138)

<0.05

83.10

 Epinephrine Aerosol

53% (n = 25)

71% (n = 113)

<0.05

 
  1. Infants with RSV diagnosis were compared at the laboratory (Group 2: SOFIA®RSV negative and PCR RSV positive) and at point-of-care testing (POCT, Group 3: SOFIA®RSV positive)
  2. Aerosol Therapy included Epinephrine, Salbutamol, Ipratropium bromide, Budesonide or normal saline
  3. NS Non Significant. Chi2 test was used for statistical comparison